Prostate Cancer: is a cancer in a man's prostate, a small walnut-sized gland that produces seminal fluid. Some types of prostate cancer grow slowly, and other types are aggressive and require radiation, hormone therapy, surgery, chemotherapy, or other treatments.
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used al...
Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for lo...
Introduction: Despite the current declines in prostate cancer mortality, African Americans (AA) continue to experience a 60% higher incidence and are twice as likely to die in comparison to m...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
DATE: June 20, 2019TIME: 8:00am PDTRetinal ganglion cells (RGCs) are projection neurons that process and transmit visual information from the retina to the brain. In a group of disea...
The advent of precision medicine largely depends on the creation of precise and accurate predictive tools. While most late-onset diseases are moderately to highly heritable, using genetic inf...
DATE: April 9, 2019TIME: 9:00 AM PDTWe will provide a general introduction to the Single-Cell Western Technology (SCW) and then present data from 2 ongoing projects from the Col...
DATE: March 26, 2019TIME: 2:00pm PDT, 5:00pm EDT Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Prodrugs are harmless in their native state, as they are not targeted by human enzymes. But they can be converted into highly toxic compounds (the “drug”) by viral or bacterial en...
DATE: January 16th, 2019TIME: 9:00AM PDT, 12:00PM EDTDr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care,to examine pat...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
DATE: July 19, 2018TIME: 09:00am PDT Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a 5 year-survival rate of approximately 6%. Despite recent...
With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for clinical support tools that aid clinicians in their decision making. To this...
Prostate cancer is one of the most common cancers in men and a major health issue in the US and Worldwide. Until recently, prostate cancer was not felt to be a hereditary disease. ...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: December 5th, 2017TIME: 6:00AM PTAndrogen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Nov...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for ca...
DATE: October, 24, 2017TIME: 7:00 AM PDT Metabolomics focuses on the chemical processes central to cellular metabolism. A robust mass spectrometry solution for screening...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used al...
Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for lo...
Introduction: Despite the current declines in prostate cancer mortality, African Americans (AA) continue to experience a 60% higher incidence and are twice as likely to die in comparison to m...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
DATE: June 20, 2019TIME: 8:00am PDTRetinal ganglion cells (RGCs) are projection neurons that process and transmit visual information from the retina to the brain. In a group of disea...
The advent of precision medicine largely depends on the creation of precise and accurate predictive tools. While most late-onset diseases are moderately to highly heritable, using genetic inf...
DATE: April 9, 2019TIME: 9:00 AM PDTWe will provide a general introduction to the Single-Cell Western Technology (SCW) and then present data from 2 ongoing projects from the Col...
DATE: March 26, 2019TIME: 2:00pm PDT, 5:00pm EDT Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Prodrugs are harmless in their native state, as they are not targeted by human enzymes. But they can be converted into highly toxic compounds (the “drug”) by viral or bacterial en...
DATE: January 16th, 2019TIME: 9:00AM PDT, 12:00PM EDTDr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care,to examine pat...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
DATE: July 19, 2018TIME: 09:00am PDT Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a 5 year-survival rate of approximately 6%. Despite recent...
With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for clinical support tools that aid clinicians in their decision making. To this...
Prostate cancer is one of the most common cancers in men and a major health issue in the US and Worldwide. Until recently, prostate cancer was not felt to be a hereditary disease. ...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: December 5th, 2017TIME: 6:00AM PTAndrogen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Nov...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for ca...
DATE: October, 24, 2017TIME: 7:00 AM PDT Metabolomics focuses on the chemical processes central to cellular metabolism. A robust mass spectrometry solution for screening...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Follow
